The impact of oral semaglutide on glycemic control and weight reduction: a database analysis of dosing effects in Japanese individuals with type 2 diabetes

The impact of oral semaglutide on glycemic control and weight reduction: a database analysis of dosing effects in Japanese individuals with type 2 diabetes

ObjectiveGLP-1 receptor agonists (GLP-1 RAs) reduce cardiovascular events in type 2 diabetes (T2D), and oral formulations improve accessibility. However, their real-world effectiveness and predictors of response remain unclear. This study assessed the proportions of individuals achieving HbA1c &...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mizuki Ishiguro, Rimei Nishimura
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Endocrinology
Subjects:	GLP-1 receptor agonists type 2 diabetes oral antidiabetic drugs semaglutide HbA1c
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1615516/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
by: Mohammad Amin Karimi, et al.
Published: (2025-05-01)

Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk
by: Sara Palazzi, et al.
Published: (2025-06-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study
by: Anders Boisen Jensen, et al.
Published: (2025-04-01)

The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort
by: Eman A. Toraih, et al.
Published: (2025-04-01)

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01)

Granuloma annulare after starting semaglutide
by: Tajena Jones, BS, et al.
Published: (2025-08-01)

Oral semaglutide for the treatment of obesity: a retrospective real-world study
by: Mitja Krajnc, et al.
Published: (2025-05-01)

The Impact of GLP-1 Receptor Agonists on Women's Reproductive Health: A Review
by: Marta Wolszczak, et al.
Published: (2025-06-01)

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
by: Hoffmann K, et al.
Published: (2025-08-01)

Contractile Effects of Semaglutide in the Human Atrium
by: Joachim Neumann, et al.
Published: (2024-08-01)

Effects of semaglutide in patients with chronic ankle instability: evidence from a prospective cohort
by: Jieyuan Zhang, et al.
Published: (2025-03-01)

Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report
by: Kenneth Brand, et al.
Published: (2025-04-01)

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
by: Andrijana Koceva, et al.
Published: (2025-01-01)

Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development
by: E. Scott Sills, et al.
Published: (2025-08-01)

Revisiting the role of novel weight management medications and bariatric surgery
by: LIANG Hui
Published: (2025-06-01)

Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in Adults with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis
by: Boram Hong, et al.
Published: (2025-07-01)

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
by: Fang Lv, et al.
Published: (2024-12-01)

Semaglutide‐Induced Hepatic Injury: A Rare Case of Drug Induced Liver Injury
by: Rupayan Kundu, et al.
Published: (2025-08-01)

Semaglutide in people with obesity and type 2 diabetes on hemodialysis: a prospective analysis of glycemic and weight outcomes
by: Akinori Hayashi, et al.
Published: (2025-05-01)

Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials
by: Hazem Ayesh, et al.
Published: (2024-08-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Effects of Zinc Supplementation on Glycemic Control in Patients with Type 1 Diabetes
by: Peyman Payami, et al.
Published: (2013-04-01)

Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature
by: Yuki Taki, et al.
Published: (2025-04-01)

A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice
by: Jonathan D. Douros, et al.
Published: (2025-10-01)

Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF
by: Patrick A. Kwaah, MBChB, et al.
Published: (2025-07-01)

Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway
by: Yawei Tian, et al.
Published: (2025-03-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Evolving Insights into Pathogenesis, Progression, and Personalized Treatment Approaches
by: Paweł Kukiełka, et al.
Published: (2025-07-01)

Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Is the Presence of a Depressive Disorder a Risk Factor for Worse Metabolic Outcomes Among Patients with Type 2 Diabetes Treated with GLP-1 Analogs?
by: Joana Nicolau, et al.
Published: (2025-07-01)

Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: A propensity-score matched analysis
by: Samuel N. Goldman, BS, et al.
Published: (2025-06-01)

SEMAGLUTIDE: Weight loss, glycaemic control and safety profile in obese patients with and without type-II diabetes-An experience from Karachi, Pakistan
by: Muhammad Y. Memon, et al.
Published: (2024-10-01)

Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes
by: Jessica Duncan, et al.
Published: (2025-09-01)

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
by: Michael J. DiStefano, et al.
Published: (2025-12-01)

Pasireotide-induced hyperglycemia in Cushing’s disease and Acromegaly: A clinical perspective and algorithms proposal
by: Przemysław Witek, et al.
Published: (2024-12-01)

GLP-1 Agonists, Willpower, and Weight Stigma: A Paradigm Shift for Obesity
by: Pablo Arrona-Cardoza
Published: (2025-08-01)

Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction
by: Yan H, et al.
Published: (2024-11-01)

The role of dulaglutide in the treatment of alcohol use disorder: a case report
by: Olivia Hill, et al.
Published: (2025-05-01)

Cross‐sectional association of irregular dietary habits with glycemic control and body mass index among people with diabetes
by: Mika Shimizu, et al.
Published: (2025-02-01)